• Login
    View Item 
    •   Home
    • Theses and Dissertations
    • Theses and Dissertations
    • View Item
    •   Home
    • Theses and Dissertations
    • Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Scholarly CommonsCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    About

    AboutCreative CommonsAugusta University LibrariesUSG Copyright Policy

    Statistics

    Display statistics

    DEVELOPMENT OF NOVEL EFFECTIVE CAR-T CELL THERAPY FOR HEPATOCELLULAR CARCINOMA

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    CaraballoGalva_gru_1907E_10240.pdf
    Size:
    8.024Mb
    Format:
    PDF
    Download
    Authors
    Caraballo Galva, Leidy Diana
    Issue Date
    2022-05
    URI
    http://hdl.handle.net/10675.2/624154
    
    Metadata
    Show full item record
    Abstract
    Liver cancer, mainly hepatocellular carcinoma (HCC), is the sixth most common cancer worldwide and the fourth most common cause of cancer death. Treatments for HCC are limited and mostly ineffective. Over the last few years, chimeric antigen receptor (CART) immunotherapy, a therapy that modifies patients own T cells with synthetic receptors that target tumor associated antigens, has demonstrated impressive efficacy in hematological tumors, but not in solid tumors yet. Multiple immunotherapeutic approaches are being studied for HCC, including chimeric antigen receptor T cell (CART) therapy. Glypican 3 (GPC3) is expressed on the surface of about 70% of HCC tumor cells, but not in normal hepatocytes. Several anti-GPC3 CARTs have been studied, but clinical outcomes have been published only for CARTs developed from the GC33 antibody. Most GPC3 CARTs are constructed from high-affinity single chain variable fragments (scFvs) because high affinity CARs might generate better anti-tumor effects. However, they may also lead to on-target/off-tumor toxicity due to low expression of target antigens in normal cells; they may incur in higher T cell exhaustion and low persistence. Some studies have shown that the anti-tumor effect of low-affinity CARs can be potentiated by the addition of appropriate co-stimulatory domains. Furthermore, for this study, we aimed to develop novel and effective low-affinity GPC3-CARTs. We sought to identify the best costimulatory domains that would give our low-affinity CARTs enhanced persistence and expansion in GPC3+ tumors while generating potent anti-tumor effects. To attain this goal, three novel mAbs, (6G11, 8F8 and 12D7) specific for HCC, were used to generate second-generation CARTs bearing the 4-1BB co-stimulatory domain. 8F8 CARTs showed the strongest in vitro and in vivo anti-tumor effects in subcutaneous tumors. Stimulated 8F8 CARTs also had higher production of IL-2 and IFN-gamma, and maintained their function after repetitive antigen stimulation. 8F8 binds an epitope close to that of GC33, but with 17X lower affinity, offering us the opportunity to comparatively study the effects of high- versus low- avidity CARTs. To further investigate whether replacing the co-stimulatory domain would enhance the effector functions and persistence of our novel CARTs, we built second-generation CARs using the co-stimulatory domains ICOS, CD28 and 4-1BB, known for their impact on CART persistence, effector function, and memory differentiation, respectively. We found that, in vitro, 8F8 and GC33 CARTs have similar function in the three different CAR designs that were tested (ICOSZ, CD28Z, and 4-1BBZ). 8F8 and GC33 had similar function, however, 8F8 BBZ CARTs exhibited a less apoptotic and less exhausted phenotype than GC33 CARTs. Furthermore, 8F8 CARTs expanded and persisted longer than GC33 when treating HepG2 tumors. Importantly, the tumor-infiltrating 8F8 CARTs maintained a better effector function for a longer time compared to high-avidity GC33 CARTs. 8F8 CARTs generated durable anti-tumor effects. Furthermore, our data suggest that our novel 8F8 CARTs might have the potential to generate potent anti-tumor effects in high-antigen clinical settings.
    Affiliation
    Biomedical Sciences
    Collections
    Theses and Dissertations

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.